RO
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES | Journal of Controlled Release | 2019 | 217 | 543 | |||
Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES | International Journal of Pharmaceutics | 2019 | 183 | 2 | |||
Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration | Antimicrobial Agents and Chemotherapy | 2017 | 404 | 1 | |||
Stability of 5P12-RANTES, A Candidate Rectal Microbicide, in Human Rectal Lavage | AIDS Research and Human Retroviruses | 2017 | 371 | 0 | |||
A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris | Protein expression and purification | 2016 | 524 | 237 | |||
Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention | Molecular pharmaceutics | 2013 | 587 | 314 | |||
CCR5 Mutations Distinguish N-Terminal Modifications of RANTES (CCL5) with Agonist versus Antagonist Activity | Journal of virology | 2012 | 589 | 0 | |||
Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use | PloS one | 2011 | 692 | 291 | |||
Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5 | Blood | 2011 | 548 | 0 | |||
"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1SF162 or simian-human immunodeficiency virus SHIVSF162-p3 do not confer resistance | Journal of virology | 2010 | 595 | 1 | |||
Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge | The Journal of infectious diseases | 2009 | 587 | 1 | |||
Chemokine analogues show suitable stability for development as microbicides | Journal of acquired immune deficiency syndromes | 2008 | 581 | 2 | |||
Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4 | Protein engineering, design & selection | 2008 | 625 | 8 | |||
Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein | Bioconjugate chemistry | 2008 | 662 | 5 | |||
Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 560 | 2 | |||
Microbicides and other topical strategies to prevent vaginal transmission of HIV | Nature reviews. Immunology | 2006 | 565 | 0 | |||
Engineering chemokines to develop optimized HIV inhibitors | Current protein and peptide science | 2005 | 513 | 0 | |||
Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors | Proceedings of the National Academy of Sciences of the United States of America | 2004 | 665 | 1 | |||
PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes | Journal of virology | 2004 | 624 | 0 | |||
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 | Science | 2004 | 608 | 1 | |||
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES | Antimicrobial agents and chemotherapy | 2003 | 608 | 2 | |||
Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines | Journal of virology | 2003 | 514 | 346 | |||
Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression | Journal of virology | 2001 | 602 | 1 | |||
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs | Journal of virology | 2000 | 498 | 2 | |||
Amino acid sequence determination by gas chromatography—mass spectrometry of permethylated peptides | Journal of chromatography | 1983 | 691 | 0 | |||
Inhibition of degradation of insulin by ophthalamic acid and by a bovine pancreatic proteinase inhibitor | Biochemical journal | 1979 | 601 | 0 | |||
The degradation of semisynthetic tritiated insulin by perfused mouse livers | Biochemical journal | 1976 | 556 | 0 |